Head-to-head · Value Score
Trimi Health vs myRocky
Two GLP-1 deals, scored on the same six factors. Trimi Health lands a Value Score of 89, myRocky a 37. Here's who gives you the honest lower price — and where each one bites back.
Trimi Health
#3 · Grade A · Great Deal
Est. first month
$99/mo
Save ~93% vs brand-namemyRocky
#395 · Grade C · Watch List
Est. first month
From $1,409/mo (brand-name)
The verdict
Trimi Health takes it on Value Score, 89 to 37 — an est. $99/mo first month, with no teaser step-up baked in. myRocky isn't out of it: Shoppers who want brand-name-only GLP-1s without insurance in 42 states.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Trimi Health | myRocky |
|---|---|---|
| Value Score | 89 (A) | 37 (C) |
| Est. first month | $99/mo | From $1,409/mo (brand-name) |
| Save vs brand-name | ~93% | — |
| Semaglutide | $99/mo | Not disclosed |
| Tirzepatide | $125/mo | Not disclosed |
| Both molecules | Yes | No |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Trimi Health
The ultra-budget pick: two-digit semaglutide and a $125 tirzepatide — one of the lowest flat tirz stickers on the whole board — shipped to all 50 states.
Why it's a deal
- Ultra-budget on both molecules — $99 semaglutide and a class-low $125 tirzepatide, flat with no teaser step-up
- Tirzepatide at $125/mo undercuts most of the flat-fee field on the priciest molecule
- Nationwide 50-state reach, so the low price isn't gated to a handful of states
The fine print
- Not LegitScript-certified — do your own pharmacy diligence before you buy on price alone
- Compounded injectable only — no FDA-approved brand-name or oral/sublingual route
- Newer brand with a thin public track record
myRocky
myRocky is a Canadian-incorporated multi-product telehealth platform (Rocky Health Inc., Ontario) that markets brand-name GLP-1s — Ozempic, Mounjaro, and Wegovy — to US patients, with no compounded products.
Why it's a deal
- Brand-name FDA-approved GLP-1s (Ozempic, Mounjaro, Wegovy) on one platform — no compounded-product risk
- LegitScript Approved
- 42-state coverage with an 8-state expansion roadmap published
- Multi-product platform for patients managing GLP-1 plus sexual health, hair loss, or mental health on one subscription
The fine print
- Expensive stacked fees: $99 consult + $99/mo program fee + ~$1,409/mo medication = ~$1,508/mo
- Canadian incorporation (Rocky Health Inc., Mississauga, ON) — verify your state's prescriber holds an active US license
- Listed pharmacy is a Canadian community pharmacy; US-fulfillment supply chain not transparent
- Brand-only — no compounded option for cost-sensitive patients
- $1,409/mo Ozempic is near retail; compare NovoCare ($349/mo Wegovy pen) or LillyDirect ($449–$699/mo Zepbound)
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Trimi Health is ranked on the Trimi Health alternatives board, and the same list for the other side is on alternatives to myRocky.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.